11 March 2023 in Nature Communications
The κ-opioid receptor (KOR) has emerged as an attractive drug target for pain management without addiction, and biased signaling through particular pathways of KOR may be key to maintaining this benefit while minimizing side-effect liabilities. As for most G protein-coupled receptors (GPCRs), however, the molecular mechanisms of ligand-specific signaling at KOR have remained unclear. To better understand the molecular determinants of KOR signaling bias, we apply structure determination, atomic-level molecular dynamics (MD) simulations, and functional assays. We determine a crystal structure of KOR bound to the G protein-biased agonist nalfurafine, the first approved KOR-targeting drug. We also identify an arrestin-biased KOR agonist, WMS-X600. Using MD simulations of KOR bound to nalfurafine, WMS-X600, and a balanced agonist U50,488, we identify three active-state receptor conformations, including one that appears to favor arrestin signaling over G protein signaling and another that appears to favor G protein signaling over arrestin signaling. These results, combined with mutagenesis validation, provide a molecular explanation of how agonists achieve biased signaling at KOR.
13 March 2025 in Nature Communications
Chronic pain and opioid overdose deaths highlight the need for non-addictive analgesics with novel mechanisms. The δ opioid receptor (δOR) is a promising target, as it lacks the respiratory depression associated with µ opioid receptor (µOR) agonists. However, early δOR full agonists caused seizures, limiting their clinical use. Partial δOR agonists may offer more controlled receptor activation than full agonists, but their development has been hindered by uncertainty regarding the molecular mechanism of partial agonism. Here we show that C6-Quino, a bitopic ligand developed through structure-based design, acts as a selective δOR partial agonist. Functional studies reveal that C6-Quino shows differential activity at G-protein and arrestin pathways and interacts with the sodium binding pocket, confirmed through cryo-EM analysis. C6-Quino demonstrates oral activity, analgesic activity in chronic pain models without causing δOR-related seizures and µOR-related adverse effects which have limited opioid usage in recent times. This discovery outlines a new strategy for developing δOR-targeted analgesics and provides a framework for optimizing signaling profiles of other Class A GPCRs.
8 January 2024 in The FEBS Journal
7 December 2020 in Alzheimer's & Dementia
Background: Alzheimer’s disease (AD) has long been described as a disease arising from progressive loss of synapses and cell death. While this is certainly true for the late stages of AD when patient present with clinical symptoms, it has increasingly become a focus of research that early AD may be paradoxically characterized by hyperexcitability and hyperactivity of neurons, specifically in hippocampal CA1 pyramidal neurons. In this study using a transgenic animal model of AD, we investigated whether an alteration in input‐specific synapse numbers could explain this early hyperactivity.Method: B6C3‐Tg(APPswe,PSEN1dE9) mice (APP/PS1) and wild‐type littermates of different ages and both sexes were injected with our novel pan‐synaptic labeling reagent (AAV1‐FAPpost) (Kuljis et al, 2019) in the dorsal hippocampal CA1 region. Labeled pyramidal cells were reconstructed and quantitative synaptic analysis across dendritic compartments was performed.Result: Even at postnatal day 21, CA1 pyramidal neurons from mutant mice showed an increase in the number of medial apical synapses (site for CA3 inputs) and a decrease in distal apical tuft synapses (site for entorhinal inputs), that may persist through adulthood. Proximal apical and basal synapses remained unaffected. Similar analysis in aged transgenic animals (13‐14 months) showed a uniform loss of synapses across all compartments.Conclusion: The compartment‐specific increase in CA3 to CA1 synapses during early development suggests that APP/amyloid‐β may be associated with abnormal synapse formation or stabilization. This increase in excitatory connectivity is consistent with hippocampal hyperexcitability that has been described in preclinical AD. This aberrant increase in CA3 may arise to compensate for the loss of entorhinal inputs and delay the onset of behavioral deficits. Our study demonstrates how AD pathology may progressively damage neural circuit function by inducing primary synaptic deficits and aberrant compensatory reweighting of other synaptic connections.